Literature DB >> 8580072

Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro.

M C Gagliardi1, G De Petrillo, S Salemi, L Boffa, M G Longobardi, P Dellabona, G Casorati, N Tanigaki, R Harris, A Lanzavecchia.   

Abstract

The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been exploited to set up a simple and reproducible method to induce a primary CTL response in vitro. We report that cultured monocytes, as well as activated T cells, pulsed with exogenous HLA-A2 binding immunogenic peptides, can induce primary peptide-specific CTL responses in vitro in a Th-independent manner. Primary viral peptide-induced CTL were HLA-A2 restricted, and recognized both peptide-pulsed target cells and targets infected with recombinant vaccinia virus expressing viral endogenous antigens. In addition, both cultured monocytes and activated T cells primed peptide-specific CD8+ T cells depleted from the CD45RO+ memory cell fraction. The efficiency of CTL priming by monocytes was dependent upon the strong up-regulation of class I, adhesion and co-stimulatory molecules occurring spontaneously upon in vitro culture. The inability of unseparated peripheral blood mononuclear cells to mount a peptide-specific CTL response could be reverted by direct co-stimulation of responding CD8+ T cells by soluble B7.1 or a stimulatory anti-CD28 antibody, that allowed a specific response to take place. Although co-stimulation via the B7-CD28 interaction appeared sufficient to trigger CTL responses, it was not essential for CTL priming, since neither anti-B7.1 mAb nor soluble CTLA-4 inhibited induction of primary CTL response. This new method for induction of specific CD8+ T cell response in vitro may be exploited in adoptive immunotherapy in cancer or in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580072     DOI: 10.1093/intimm/7.11.1741

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

1.  Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.

Authors:  J Joseph Melenhorst; Phillip Scheinberg; Ann Williams; David R Ambrozak; Keyvan Keyvanfar; Melody Smith; J Philip McCoy; Nancy F Hensel; Daniel C Douek; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-06       Impact factor: 5.742

2.  Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes.

Authors:  D R Drake; J M Moser; A Hadley; J D Altman; C Maliszewski; E Butz; A E Lukacher
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.

Authors:  Vincenzo Russo; Arcadi Cipponi; Laura Raccosta; Cristina Rainelli; Raffaella Fontana; Daniela Maggioni; Francesca Lunghi; Sylvain Mukenge; Fabio Ciceri; Marco Bregni; Claudio Bordignon; Catia Traversari
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

4.  Cross-linking of Fc(gamma)-receptor on monocytes inhibits hepatitis C virus-specific cytotoxic T-lymphocyte induction in vitro.

Authors:  T Kanto; N Hayashi; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; M Hori
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

5.  Theileria annulata-transformed cell lines are efficient antigen-presenting cells for in vitro analysis of CD8 T cell responses to bovine herpesvirus-1.

Authors:  Jane Hart; Niall D MacHugh; W Ivan Morrison
Journal:  Vet Res       Date:  2011-12-19       Impact factor: 3.683

6.  Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.

Authors:  M Lucchiari-Hartz; P M van Endert; G Lauvau; R Maier; A Meyerhans; D Mann; K Eichmann; G Niedermann
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.